The Medical Advisor

Series Hub · Living Review · September 2026 What already has trials, guidelines, or large human datasets — and what that does not authorize. Aspirin in PI3K-altered colorectal cancer is now guideline medicine. Metformin and statins are mixed. GLP-1 receptor agonists are the 2026 observational wave. This hub exists so “repurposed” stops meaning one bucket. Read this first. OneDayMD pages in this series are educational syntheses for patients, caregivers, and clinicians. They are not personal medical advice, not a protocol to self-start, and not a substitute for the treating oncologist. Off-label use, when discussed, is described so it can be raised inside a supervised relationship — not so it can replace one. Evidence badges are defined below. Observational signals can be large and still be wrong. On this page Three doors Why this series exists Evidence badges The ranked stack Part A — High-evidence agents Part B — GLP-1 / incretin oncology GLP-1 hold / continue fl...

Medically Reviewed by: Dr. Frank Yap, MD | Written by: OneDayMD Editorial Team | Published: March 2026 | Last updated: October 6, 2026 Quick Answer As of October 2026, tirzepatide (Zepbound) is the strongest FDA-approved option at about 20–21% average weight loss, ahead of semaglutide (Wegovy) at about 15% (20.7% at the new 7.2 mg dose). Retatrutide, a triple agonist, reached 28.3% at 80 weeks in Phase 3 but is not FDA-approved ; Lilly plans to file in Q1 2027. What changed in this update (Oct 2026): replaced pre-Phase-3 estimates with TRIUMPH-1/2/3 results; corrected retatrutide launch timing (not before late 2027); added Wegovy HD, the Wegovy pill, Foundayo and CagriSema context; removed claims sourced only from research-peptide vendors, forum posts and unverified preprints; added CEBM evidence tiers, FAQ and an AI-prompt guide. Contents At-a-glance comparison How the three work What the trials show (and don't) Retatrutide: status in October 2026 Muscle and lean...

OneDayMD • The Medical Advisor A single starting point for exploring OneDayMD's health, wellness, longevity, nutrition, cancer, metabolic medicine, emerging therapies and digital-health research. Quick Answer OneDayMD is an independent health-information and research-synthesis platform covering conventional medicine, integrative health, longevity, nutrition, supplements, metabolic medicine, cancer research, emerging therapies and digital health. This Master Guide is the site's central navigation page: use it to find the right topic hub, then move from a broad guide to the specific evidence, study, therapy, supplement, condition or research question you are investigating. On this page Start Here · Core Health Hubs · Cancer & Oncology · Nutrition & Supplements · Longevity · GLP-1 & Metabolic Health · DMSO ·...